To evaluate whether TIL present in the infusion product were also reactive toward CLL antigens, we first isolated CD5+CD19+ B cells from peripheral blood mononuclear cells (PBMCs) collected at the time of tumor harvest and before obinutuzumab administration. This evidence concerns the gene CD5 and B-cell chronic lymphocytic leukemia.